Abstract Background
Introduction
Patients suffering from severe renal diseases for a variety of reasons may finally progress to develop end-stage renal failure. During the last decades, kidney transplantation has become the first choice of treatment for these patients; however because of donor organ shortage, patients are still dying on the waiting list. The major donor pool consists of kidneys recovered from deceased brain-dead donors (DBD), although living donation and donation after cardiac death (DCD) have emerged as alternative sources. Kidneys from deceased donors have an inferior transplant function, decreased survival rates and a higher risk to develop acute rejection as compared with kidneys obtained from healthy living (un)related donors (1-4). Despite the beneficial effects of modern immunosuppressive drugs, acute rejection can still not be completely prevented (5) . One of the major goals in renal transplantation is to minimize the use of immunosuppressants because of toxic side effects, cardiovascular sequelae, and infectious complications. Also, identifying biomarkers associated with acute rejection will contribute to a better understanding of the relevant underlying processes leading to graft injury. Consequently, this might result in the development of new drug targets to prevent or treat acute rejection after renal transplantation. Currently, only recipient related biomarkers such as donor-specific antibodies and panel reactive antibodies are associated with acute rejection. Although it is well established that donor parameters play an important role in graft injury and posttransplant survival, to our knowledge no specific biomarkers in the donor which are associated with acute rejection after transplantation in the recipient have been identified yet. Activation of the complement system has been shown to be an important mediator of renal transplant related injury. During transplantation, both ischemia and ischemia-reperfusion mediated injury result in complement activation. Consequently, complement activation products such as C5b-9 may induce renal damage. Furthermore, complement activation products are able to induce upregulation of proinflammatory substances and chemokinesis of infiltrating leukocytes in the kidney (6;7). Also after transplantation, the complement split products C3a and C5a are potent activators of T-cells by enhancing the capacity of dendritic cells for allospecific T cell stimulation through specific receptors (8;9) . The aim of this study was to asses the role of complement activation in the donor on the outcome of renal transplant function and survival after transplantation in the recipient.
Results

Patients and plasma samples
Between November 1, 2005 and August 17, 2007, a total of 376 deceased kidney donors 16 years of age or older were included in the trial. In this study cohort, 232 kidney donors were used while 144 donors were excluded, because no donor plasma samples were available. Donor characteristics of the 232 donors (and 464 recipients) with available plasma samples are shown in Table 1 . Baseline characteristics of donors and recipients included in the present study cohort were checked for selection bias and did not differ significantly from the overall group.
C5b-9, C4d, Bb and Mannan Binding Lectin Plasma Levels
As complement activation by all three pathways finally result in activation of the terminal complement sequence, we first measured levels of C5b-9. Significantly higher levels of C5b-9 were found in deceased donors compared with plasma levels from living donors and controls (Table 2, Figure 1 ). No significant complement activation was found in living donors compared with controls. Additionally, Spearman's correlation showed that donor C5b-9 was not significantly correlated with donor serum creatinine (r=-0.020, P=0.670).
To determine the contribution of the classical/lectin and/or alternative pathway of complement activation, C4d and Bb were analyzed, respectively. Both C4d and Bb were significantly higher in deceased donors as compared with living donors and controls. The median mannan binding lectin (MBL) concentration in our donor cohort was 653 ng/ml which is comparable with populations studied by others (10;11). Levels of MBL were not significantly higher compared with controls. However, MBL levels were significantly lower in living donors compared with deceased donors and controls due to the relatively large amount of MBLdeficient living donors (Table 2, Figure 1 ). 
Donor complement activation and transplant outcome
For recipients whose kidney had biopsy-proven acute rejection, donor C5b-9 levels were significantly higher compared with donor levels from nonrejecting kidneys ( Table 2) . Univariate regression analysis showed a significant association between higher donor C5b-9 levels and acute graft rejection. Of donors with C5b-9 levels above the median, 31% (71/232) developed acute rejection compared with 17% (40/232) in donors with a C5b-9 level below the median. Next, a multivariate analysis was performed with covariates that were found to be significantly associated with acute rejection by univariate analysis. These included in the following: preservation method (machine perfusion (MP) vs cold storage), human leukocyte antigen (HLA) mismatches, donor type (DCD vs. DBD), donor age, recipient age, panel reactive antibodies percentage, the number of previous transplants of the recipient, cold ischemic time, duration of pretransplant dialysis and the cause of death of the donor (trauma versus other causes). The use of immunosuppressive drugs was not included as a covariate in our model, as univariate analyses revealed that this was not a risk factor for acute rejection in our study. When a multivariate regression model analysis was applied, C5b-9 was found to be an independent factor associated with acute graft rejection (odds ratio 1.506, 95% confidence interval 1.037 -2.187, Table 3 ), next to human HLA mismatching (odds ratio 1.316, 95% confidence interval 1.111 -1.560, Table 3 ). A receiver operator characteristic (ROC) curve was constructed to assess cut-off points for C5b-9 as a predictor of acute rejection (Figure 2 ). ROC curve analysis demonstrated an area under the curve estimate of 0.57 which indicates that donor C5b-9 is not a strong predictor of acute rejection. When the median (858 ng/ml) was applied, the positive predictive value was 30% and the negative predictive value 83%. No association was found between levels of donor C5b-9 and primary non-function (PNF), delayed graft function (DGF) and graft survival during the first year after transplantation ( Table 2 ). The type of rejection was documented according to the Banff classification of a subset of 33 of the 111 rejecting kidneys. Interestingly, this subset revealed that donor kidneys exposed to high C5b-9 levels in deceased donors are prone to develop vascular rejection more frequently in the recipient (Table 4 ). Spearman's correlation showed that both C4d and Bb levels were significantly correlated with C5b-9 in donor plasma (C4d/C5b-9 r=0.416, P<0.001; Bb/C5b-9 r=0.582 P<0.001). However, C4d and Bb were not associated with acute rejection, PNF, DGF and graft survival after renal transplantation in the recipient. Partial correlation showed that C4d is associated with C5b-9 independent of MBL (C4d/C5b-9 corrected for MBL r=0.385, P<0.001). Also, MBL levels in the donor were not associated with posttransplant outcome. For additional analysis we divided our study population into a group above and below 400 ng/ml. MBL levels below 400 ng/ml was shown earlier to be closely related to MBL variant alleles (A/O, O/O), while MBL above 400 ng/ml was related to MBL wild type (A/A) (10) . Using this cut-off of 400 ng/ml 40.4% of our donor population had a low MBL and 59.6% a high MBL level, which is comparable to the frequency of variant alleles determined by others (11) . No significant difference in graft survival was observed in the first year after transplantation using both median and 400 ng/ml of MBL as a cutoff (Table 2 ). 
is an independent factor associated with acute rejection after transplantation, next to HLA mismatch (P=0.035).
Variable
Odds ratio (95% CI) P value Donor kidneys that are exposed to a high C5b-9 in the donor are prone to develop vascular rejection more frequently in the recipient.
Discussion
This study shows that complement C5b-9 levels in deceased donor plasma is associated with acute rejection in the recipient after renal transplantation. In DBD and DCD donors, significant complement activation was found. No significant association was found between donor complement activation levels and PNF, DGF or graft survival in the first year after transplantation in recipients. Chronic allograft failure is affected by different variables including donor condition, ischemiareperfusion injury and graft rejection. Acute rejection has been shown to be negatively associated with long term renal allograft dysfunction. Despite HLA-matching in clinical renal transplantation and better immunosuppression, the occurrence of acute rejection episodes can still not be completely prevented. Independent of HLA-matching, we found that C5b-9 in the plasma of the deceased donor is significantly associated with acute rejection in the first year after transplantation in the recipient. As part of the innate immune system, complement activation is an important mediator of renal transplant-related injury in the recipient. It has been shown that renal ischemia-reperfusion injury is in part complement mediated and that local expression of the central complement component C3 is involved in graft rejection and affects graft survival after transplantation (12;13). Moreover, inhibition of complement activation in animal models has been shown to prevent rejection associated injury (14;15). In humans, complement activation in the recipient has been demonstrated as evidenced by the deposition of C4d in peritubular capillaries in rejecting allografts, now part of the Banff classification (16) . Also, activation of the lectin pathway is important, as low recipient MBL levels are beneficial for graft survival (10) . Taken together, these studies clearly show that complement is involved in renal transplant rejection in the recipient. In contrast to the previous studies that focused on the recipient, we now demonstrated that activation of systemic complement in deceased donors partially determines the risk of transplant rejection in the recipient. In living donors, no significant complement activation was found, which indicates that anaesthesia or hospitalization are not responsible for the increased C5b-9 levels found in deceased donors. To determine which complement pathways are activated in the donor, both C4d (classical/lectin) and Bb (alternative) were correlated with the extent of C5b-9 generation. The association of C4d with C5b-9 was independent of MBL, suggesting that generation of C4d can be ascribed mainly to classical pathway activation. However the role of ficolins, potent activators of the lectin pathway, can not be excluded. How the classical pathway is triggered in deceased donors remains unclear but it might be activated by C-reactive protein, although no association between complement activation and C-reactive protein was found in this study (17) . After classical pathway activation, the alternative pathway amplification loop may be triggered, leading to generation of Bb. Besides, the alternative pathway might have been activated by lipopolysaccharide, which may be found in some deceased donors (18) . We reason that complement activation products are generated in deceased donors and may directly or indirectly initiate renal injury. Recently we found that complement becomes deposited in the kidney already before organ retrieval in kidneys from brain-dead donors (19) . In addition, also Naesens et al. found increased complement deposition in preimplantation biopsies (20) . Besides local expression of complement as found by our group and Naesens et al., also systemic complement activation might be responsible for the deposition of complement in the kidney before organ recovery. This is supported by the finding that donor kidneys exposed to high C5b-9 levels in deceased donors are prone to develop vascular rejection more frequently in the recipient. We envision that complement activation products in the blood, C3a, C5a and C5b-9, induce immune activation in the donor kidney. First, mainly C5a, but also C3a, are potent chemotactic complement split products which are able to activate primarily peripheral neutrophils, monocytes and macrophages through specific receptors (21;22) . This might explain for instance the finding of an increased polymorphonuclear neutrophil influx in kidneys from brain-dead donors (23) . Second, anaphylatoxins and sC5b-9 upregulate several immunomodulatory factors on vascular endothelium through their receptors, including P-selectin, IL-8 and MCP-1 (24-27). Third, the direct lytic effect of the C5b-9 complex through disturbance of the cellular membrane potential on the renal vaculature is a potent mechanism of injury to the graft itself. Fourth, complement split products, covalently deposited in the donor kidney, could be potent activators of B and T cells in the recipient after transplantation (28) (29) (30) . Finally, both C3a and C5a are able to stimulate dendritic cells through their receptors, increasing T-cell responses (8;9). We are aware that the association found in this study does not necessarily reflect causality and that the proposed mechanisms of complement-dependent renal injury described here are only speculative. Taken together, our results indicate that systemic complement is activated in both DBD and DCD donors and that a higher C5b-9 level is associated acute rejection after transplantation in the recipient. Although an independent significant association was found, one has to be cautious in the interpretation of our data since our results are preliminary and have to be validated in other study cohorts. Furthermore, as revealed by ROC-curve analysis, C5b-9 is unlikely to be a good predictor of acute rejection in the recipient. However, complement activation in the donor might be involved in the pathogenesis of renal injury leading to acute rejection in the recipient. Whether targeting complement activation in the donor may reduce or even prevent acute rejection episodes in the recipient needs to be studied.
Materials and methods
Patients and study design
This study is a substudy of the international randomized controlled trial which investigated the effect of hypothermic MP versus static cold storage preservation in kidney transplantation and included the Netherlands, Belgium, and the federal state of North Rhine-Westphalia in Germany (The Machine Preservation Trial). Between November 1, 2005 and August 17, 2007, all consecutive deceased donor kidney pairs that met the initial inclusion criteria were eligible for randomization by Eurotransplant, an international organ exchange organization in Europe. Both DBD and controlled DCD donors (Maastricht category III) were included (31) . From each donor, one kidney was randomly assigned to MP and the contralateral kidney to cold storage. The organs could be transplanted into any recipient within the Eurotransplant region (32) . For further details on study design, inclusion criteria, and recipient follow up we refer to our previous publication (33) .
Sample collection
Whole blood samples were drawn from 232 DBD and DCD donors prior to organ recovery in the donor and collected in EDTA tubes to prevent further in vitro complement activation. In DCD donors, samples were taken just before ventilator switch-off. In brain-dead donors, samples were taken prior to systemic cold perfusion. In 20 living donors, plasma samples were obtained shortly before kidney donation. Plasma from 20 healthy volunteers served as controls. Samples were transported on ice, centrifuged to obtain plasma, and the plasma's were stored in aliquots at -80°C until further analysis. In each assay, fresh frozen plasma samples were used for analysis.
C5b-9 ELISA
Nunc Maxisorp 96-well plates were coated with monoclonal mouse anti human C5b-9 (Dako, Glostrup, Denmark) overnight at 4°C. After 1 hr blocking and washing, plasma samples were incubated for 1 hr at 37°C. After washing, wells were subsequently incubated with polyclonal goat-anti-human C5 (Quidel, San Diego, USA), horseradish peroxidase-conjugated rabbit anti-goat immunoglobulin and tetramethylbenzidine as a substrate. Between incubation steps, wells were washed with PBS containing 0.05 % Tween-20. After the reaction was stopped with 1 M H 2 SO 4 , the amount of reacted substrate was measured at OD 450 nm. A standard curve was made using serial dilutions of a Zymosan activated human serum pool. The amount of C5b-9 in measured samples was determined from the standard curve with a known concentration of C5b-9.
C4d, Bb and MBL ELISA
To differentiate between complement activation pathways we determined stable activation products of the three known pathways: C4d (classical/lectin) and Bb (alternative). Additionally, MBL plasma concentrations were measured because earlier studies have shown an involvement of MBL levels in renal allograft survival (10) . C4d and Bb were determined using commercially available modified enzyme-immunoassays according to the manufacturer's protocol (Quidel, CA). Plasma levels of MBL were quantified by sandwich ELISA. Nunc Maxisorp 96-well plates were coated with monoclonal mouse anti human MBL 3E7 (Hycult, Uden, The Netherlands) overnight at room temperature. After 1 hr blocking and washing, plasma samples were incubated for 1 hr at 37°C. After washing, wells were subsequently incubated with polyclonal goat-anti-human MBL 3E7-DIG, horseradish peroxidase-conjugated sheep anti-DIG immunoglobulin and tetramethylbenzidine as a substrate. Between incubation steps, wells were washed with PBS containing 0.05 % Tween-20. After the reaction was stopped with 1 M H 2 SO 4 , the amount of reacted substrate was measured at OD 450 nm. A standard curve was made using serial dilutions of a human serum pool with known MBL concentration. MBL in plasma samples was determined from the standard curve against an internal control.
Study end points
The primary end points in this study were: delayed graft function (DGF, defined as the need for dialysis during the first week after transplantation), primary non-function (PNF, defined as non-functioning of the allograft from transplantation onwards), death censored graft survival and biopsy proven acute rejection during the first year after transplantation.
Statistical analysis
The nonparametric Kruskal-Wallis test, followed by Mann-Whitney U tests were performed to compare C5b-9, C4d, Bb and MBL concentrations between controls, living and deceased donors. Spearman's correlation analysis was used to associate C5b-9 levels with respectively C4d, Bb or MBL levels in deceased donors. Mann-Whitney U tests were performed to compare donor C5b-9, C4d, Bb and MBL concentrations between recipients with and without acute rejection, DGF and PNF. Kaplan-Meier survival curves and logrank tests were performed to assess whether 1 year death censored graft survival was significantly different in recipients whose kidney donor had C5b-9, C4d, Bb and MBL concentrations above or under the median. For those univariate associations that were found to be statistically significant, a multivariate model was built. Since one donor gave kidneys to two recipients, this could potentially have biased our results. Therefore, we incorporated a normal gamma frailty term in the multivariate analysis, to account for the within-donor dependence structure of our data (for each left + right kidney in a pair, donor characteristics were by definition exactly the same, but recipients were different). Statistical analyses were performed using SPSS (version 16.0) and R (version 2.7.1) software packages. Two-sided p-values under 0.05 were considered to indicate statistical significance.
